• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
WAN Ping, SUN Jianguo, HAO Gang, ZHANG Xiaoxuan, XIAO Dawei, LIU Zhihong, WANG Guangji. Determination of rhein in plasma,urine and feces by HPLC-fluorescence detection and its pharmacokinetics in healthy volunteers[J]. Journal of China Pharmaceutical University, 2013, 44(1): 73-76. DOI: 10.11665/j.issn.1000-5048.20130112
Citation: WAN Ping, SUN Jianguo, HAO Gang, ZHANG Xiaoxuan, XIAO Dawei, LIU Zhihong, WANG Guangji. Determination of rhein in plasma,urine and feces by HPLC-fluorescence detection and its pharmacokinetics in healthy volunteers[J]. Journal of China Pharmaceutical University, 2013, 44(1): 73-76. DOI: 10.11665/j.issn.1000-5048.20130112

Determination of rhein in plasma,urine and feces by HPLC-fluorescence detection and its pharmacokinetics in healthy volunteers

More Information
  • This study established a HPLC-fluorescence detection(HPLC-FLD) assay for determining of rhein in human plasma,urine and feces on a reversed-phase C18 column with a mobile phase of methanol-acetonitrile-1% acetic acid (61 ∶15 ∶24).HPLC-FLD was performed at excitation wavelength 440 nm and emission wavelength 520 nm for rhein and the internal standard.Calibration curves were linear over the ranges of 0.05-10.00 μg/mL in plasma,0.10-25.00 μg/mL in urine and 0.20-100.00 μg/mL in feces.The lowest limit of quantification for rhein was 0.05 μg/mL in plasma,0.10 μg/mL in urine and 0.20 μg/mL in feces.The recovery of this method was greater than 80%.The main pharmacokinetic parameters cmax,tmax,AUC0-∞,t1/2 and MRT were (16.0±3.4) μg/mL,(4.0±0.6) h,(152.7±45.7) μg ·h/mL,(5.5±1.1) h and (8.9±2.2) h,respectively.The accumulative excretion rate of rhein in urine and feces were (8.19±1.84)% and 11.00%,separately.This assay was proved to be convenient,accurate,sensitive and suitable for mass determination of biological samples.
  • Related Articles

    [1]CHEN Feihong, ZHAO Deming, GOU Shaohua. Research progress on the antitumor effects of platinum-based chemo-immunotherapies[J]. Journal of China Pharmaceutical University, 2024, 55(1): 26-35. DOI: 10.11665/j.issn.1000-5048.2023120201
    [2]XU Yungen. Advances in drug development based on immunoregulation[J]. Journal of China Pharmaceutical University, 2024, 55(1): 1-4. DOI: 10.11665/j.issn.1000-5048.2024022601
    [3]YU Dongmei, GUO Wei, LEI Wen, GE Yaoyao, CHEN Yucong, GAO Xiangdong, YAO Wenbing. Advances of lncRNA in immune cells and autoimmune diseases[J]. Journal of China Pharmaceutical University, 2017, 48(3): 371-376. DOI: 10.11665/j.issn.1000-5048.20170319
    [4]LIANG Xiao-qing, SHI Chen-yang, WANG Ke, HE Xin, LIU Si-guo, HUANG Xiao-feng, LIU Yu. Anti-angiogenesis and anti-tumor activity of the fully human anti-VEGF165 monoclonal antibody obtained from the five-feature transgenic mice[J]. Journal of China Pharmaceutical University, 2012, 43(6): 560-566.
    [5]Tumor microenvironment:A novel target for antitumor activity of polysaccharides[J]. Journal of China Pharmaceutical University, 2010, 41(1): 1-10.
    [8]Effects of Mixed Nucleotide on Acute Hepatic Injury and Immunoregulation in Mice[J]. Journal of China Pharmaceutical University, 2001, (6): 44-47.
    [9]Immunomodulating Activity of Yang Zheng He Ji[J]. Journal of China Pharmaceutical University, 1995, (1): 37-40.
    [10]The Immunoregulative Effect of the Synthetic Artifact of Royel Jelly Acid[J]. Journal of China Pharmaceutical University, 1991, (2): 117-118.
  • Cited by

    Periodical cited type(3)

    1. 曾雪亮,钟文敏,李蓓. 异甘草酸镁联合疗法治疗慢性乙型肝炎的效果及安全性的meta分析. 中国当代医药. 2021(30): 13-17 .
    2. 高华,何海妮,刘莉娜. 异甘草酸镁注射液对耐多药结核鼠T淋巴细胞亚群及血清抗体的影响. 临床和实验医学杂志. 2020(22): 2382-2385 .
    3. 柏杰. 双环醇联合异甘草酸镁治疗失代偿期肝硬化疗效观察. 智慧健康. 2020(31): 115-116 .

    Other cited types(1)

Catalog

    Article views (1562) PDF downloads (2047) Cited by(4)

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return